Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Malignant Solid Tumor: early-phase trial registry
3 of 4 indexed Advanced Malignant Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Advanced Malignant Solid Tumor: 4 US clinical trials tracked, 3 recruiting.
Advanced Malignant Solid Tumor is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Epizyme, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-malignant-solid-tumor
OPEN 3 | RECR 75% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Advanced Malignant Solid Tumor lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Malignant Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Malignant Solid Tumor is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Repertoire Immune Medicines
NCT07293754
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Pilatus Biosciences
NCT07337525
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Epizyme
NCT04241835
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
BioNTech SE
NCT06150183
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Malignant Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Malignant Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Malignant Solid Tumor page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Advanced Malignant Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Epizyme sponsors the most Advanced Malignant Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Epizyme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Malignant Solid Tumor condition card totals 4 registered trials; most-linked intervention PD-1 / PD-L1 monoclonal antibody; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.